1. Drug exposure for PDA closure in France: a prospective, cohort-based, analysis.
- Author
-
Iacobelli, Silvia, Lorrain, Simon, Gouyon, Béatrice, Gambacorta, Silvia, Laforgia, Nicola, Gouyon, Jean-Bernard, and Bonsante, Francesco
- Subjects
LOW birth weight ,CHI-squared test ,CONFIDENCE intervals ,FISHER exact test ,LONGITUDINAL method ,NEONATAL intensive care ,SCIENTIFIC observation ,PATENT ductus arteriosus ,NEONATAL intensive care units ,TREATMENT effectiveness ,DATA analysis software ,DESCRIPTIVE statistics ,ODDS ratio - Abstract
Purpose: To describe the exposure to drugs used for the treatment of patent ductus arteriosus (PDA) in a large cohort of preterm infants born before 32 weeks of gestation. Methods: A prospective observational cohort analysis was conducted during 2 years in 28 French level 3 NICU using the same computerized order-entry system. The main outcome was "a medically treated PDA," defined as exposure to ibuprofen, indomethacin, or paracetamol prescribed with the indication of PDA closure. Secondary outcomes were as follows: time of the first treatment administration; total exposure to furosemide during hospitalization; and rate of PDA refractory to pharmacological closure. Results: The study cohort consisted of 2614 infants. Among them, 474 (18.1%) received a medical treatment for PDA, with a mean postnatal age at treatment of 4.3 ± 6.6 days. The drug used as a first-line treatment was ibuprofen in 89.5% and paracetamol in 10.5%. One hundred and ninety-five infants (7.4%) had a PDA refractory to pharmacological closure. At the multivariate analysis, factors associated with PDA refractory to pharmacological closure (OR; 95% CI) were as follows: gestational age (GA) (0.81; 0.72–0.90), paracetamol as the first-line treatment (0.32; 0.15–0.68), and pharmacological treatment before 48 h of life (0.63; 0.43–0.94). 24.6% of the study cohort was exposed to furosemide (cumulative dose 6.5 ± 12.6 mg/kg). Variables significantly associated with higher cumulative doses of furosemide were lower GA and ibuprofen treatment (both p < 0.0001). Conclusion: Drug utilization patterns in infants with PDA vary among centers. Pharmacoepidemiology studies can provide new information on factors associated with PDA refractory to medical treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF